TISIDB

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Basic function annotation. > Subcellular Location, Domain and Function > Gene Ontology > KEGG and Reactome Pathway

> Subcellular Location, Domain and Function [ TOP ]
Subcellular Location	Cytoplasm Preautophagosomal structure membrane Peripheral membrane protein Note=Recruited to omegasomes membranes by WIPI2. Omegasomes are endoplasmic reticulum connected strutures at the origin of preautophagosomal structures. Localized to preautophagosomal structure (PAS) where it is involved in the membrane targeting of ATG5. Localizes also to discrete punctae along the ciliary axoneme.
Domain	PF08614 Autophagy protein 16 (ATG16) PF00400 WD domain
Function	Plays an essential role in autophagy: interacts with ATG12-ATG5 to mediate the conjugation of phosphatidylethanolamine (PE) to LC3 (MAP1LC3A, MAP1LC3B or MAP1LC3C), to produce a membrane-bound activated form of LC3 named LC3-II. Thereby, controls the elongation of the nascent autophagosomal membrane (PubMed:24553140, PubMed:23376921, PubMed:24954904, PubMed:27273576, PubMed:23392225). Regulates mitochondrial antiviral signaling (MAVS)-dependent type I interferon (IFN-I) production (PubMed:25645662). Negatively regulates NOD1- and NOD2-driven inflammatory cytokine response (PubMed:24238340). Instead, promotes with NOD2 an autophagy-dependent antibacterial pathway (PubMed:20637199). Plays a role in regulating morphology and function of Paneth cell (PubMed:18849966).

> Gene Ontology [ TOP ]
Biological Process	GO:0000045 autophagosome assembly GO:0006914 autophagy GO:0007033 vacuole organization GO:0016236 macroautophagy GO:0019058 viral life cycle GO:0019079 viral genome replication GO:0039689 negative stranded viral RNA replication GO:0039694 viral RNA genome replication GO:0039703 RNA replication GO:0044033 multi-organism metabolic process GO:0044034 multi-organism biosynthetic process GO:0051259 protein oligomerization GO:0051260 protein homooligomerization GO:1905037 autophagosome organization
Molecular Function	GO:0019787 ubiquitin-like protein transferase activity
Cellular Component	GO:0000407 pre-autophagosomal structure GO:0000421 autophagosome membrane GO:0005776 autophagosome GO:0005929 cilium GO:0005930 axoneme GO:0034045 pre-autophagosomal structure membrane GO:0044441 ciliary part GO:0097014 ciliary plasm

> KEGG and Reactome Pathway [ TOP ]
KEGG	hsa04140 Regulation of autophagy hsa04621 NOD-like receptor signaling pathway
Reactome	R-HSA-2262752: Cellular responses to stress R-HSA-1632852: Macroautophagy

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Literatures that report relations between ATG16L1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.

> Text Mining [ TOP ]
There is no record.

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.

> High-throughput Screening

[ TOP ]

Statistical results of ATG16L1 in screening data sets for detecting immune reponses.

PMID	Screening System	Cancer Type	Cell Line	Data Set	Statistical Results	Relation to immunity
29301958	CRISPR-Cas9	melanoma	B16F10	Pmel-1 T cell	logFC: -2.48; FDR: 0.04630	Resistant to T cell-mediated killing
29301958	CRISPR-Cas9	melanoma	B16F10	OT-1 T cell	NA/NS	NA/NS
28783722	CRISPR-Cas9	melanoma	Mel624	2CT-CRISPR	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX+Anti-PD1	NA/NS	NA/NS
28723893	CRISPR-Cas9	melanoma	B16	GVAX	NA/NS	NA/NS
25691366	RNAi	Breast cancer	MCF7	Luc-CTL assay	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Primary screen	NA/NS	NA/NS
24476824	shRNA	melanoma	B16	Secondary screen	NA/NS	NA/NS

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets. > Expression difference between responders and non-responders > Mutation difference between responders and non-responders

> Expression difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the expression difference of ATG16L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	Log2 (Fold Change)	P value
1	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	14	12	-0.064	0.721
2	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	6	5	0.06	0.969
3	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	7	-0.152	0.89
4	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0.229	0.338
5	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	-0.062	0.97
6	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0.595	0.772
7	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	26	23	0.13	0.712
8	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	15	11	0.103	0.942
9	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	11	12	0.157	0.921
10	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	4	8	0.549	0.622
11	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	2	0	0	1
12	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	2	8	0.921	0.588
13	29443960	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	68	230	-0.002	0.967

> Mutation difference between responders and non-responders

[ TOP ]

Points in the above scatter plot represent the mutation difference of ATG16L1 in various data sets.

No	PMID	Cancer type	Group	Drug	# Res	# NRes	% Mut/Res	% Mut/NRes	% Diff (R vs NR)	Pval
1	25765070	Non-small cell lung cancer (NSCLC)	all	Anti-PD-1 (pembrolizumab)	14	17	0	0	0	1
2	25765070	Non-small cell lung cancer (NSCLC)	smoking	Anti-PD-1 (pembrolizumab)	10	3	0	0	0	1
3	25765070	Non-small cell lung cancer (NSCLC)	non-smoking	Anti-PD-1 (pembrolizumab)	4	14	0	0	0	1
4	26359337	Melanoma	all	Anti-CTLA-4 (ipilimumab)	27	73	3.7	1.4	2.3	0.469
5	26359337	Melanoma	BRAFi	Anti-CTLA-4 (ipilimumab)	0	14	0	0	0	1
6	26359337	Melanoma	non-BRAFi	Anti-CTLA-4 (ipilimumab)	27	59	3.7	1.7	2	0.532
7	26997480	Melanoma	all	Anti-PD-1 (pembrolizumab and nivolumab)	21	17	0	0	0	1
8	26997480	Melanoma	MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	8	6	0	0	0	1
9	26997480	Melanoma	non-MAPKi	Anti-PD-1 (pembrolizumab and nivolumab)	13	11	0	0	0	1
10	28552987	Urothelial cancer	all	Anti-PD-L1 (atezolizumab)	9	16	0	0	0	1
11	28552987	Urothelial cancer	smoking	Anti-PD-L1 (atezolizumab)	5	9	0	0	0	1
12	28552987	Urothelial cancer	non-smoking	Anti-PD-L1 (atezolizumab)	4	7	0	0	0	1
13	29033130	Melanoma	all	Anti-PD-1 (nivolumab)	38	27	2.6	3.7	-1.1	1
14	29033130	Melanoma	NIV3-PROG	Anti-PD-1 (nivolumab)	22	13	4.5	7.7	-3.2	1
15	29033130	Melanoma	NIV3-NAIVE	Anti-PD-1 (nivolumab)	16	14	0	0	0	1
16	29301960	Clear cell renal cell carcinoma (ccRCC)	all	Anti-PD-1 (nivolumab)	11	13	0	0	0	1
17	29301960	Clear cell renal cell carcinoma (ccRCC)	VEGFRi	Anti-PD-1 (nivolumab)	6	1	0	0	0	1
18	29301960	Clear cell renal cell carcinoma (ccRCC)	non-VEGFRi	Anti-PD-1 (nivolumab)	5	12	0	0	0	1

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of ATG16L1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.

> Lymphocyte [ TOP ]

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of ATG16L1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by ATG16L1. > Immunoinhibitor > Immunostimulator > MHC molecule

> Immunoinhibitor [ TOP ]

> Immunostimulator [ TOP ]

> MHC molecule [ TOP ]

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of ATG16L1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene. > Chemokine > Receptor

> Chemokine [ TOP ]

> Receptor [ TOP ]

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Distribution of ATG16L1 expression across immune and molecular subtypes. > Immune subtype > Molecular subtype

> Immune subtype [ TOP ]

> Molecular subtype [ TOP ]

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Associations between ATG16L1 and clinical features. > Overall survival analysis > Cancer stage > Tumor grade

> Overall survival [ TOP ]

> Stage [ TOP ]

> Grade [ TOP ]

Summary
Symbol	ATG16L1
Name	autophagy related 16-like 1
Aliases	WDR30; FLJ10035; ATG16A; APG16L; ATG16L; APG16 autophagy 16-like (S. cerevisiae); ATG16 autophagy related 16 ......
Chromosomal Location	2q37.1
External Links	HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content	Drugs targeting ATG16L1 collected from DrugBank database.

> Drugs from DrugBank database [ TOP ]
There is no record.

Browse ATG16L1